Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies.
Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind both CD19 and Fc"RIIb for the treatment of several I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus.
The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; and ZB001, an anti-IGF-1R monoclonal antibody.
Zenas BioPharma, Inc. was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023.
The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Reported date | EPSChange YoY | EstimateSurprise |
---|---|---|
Feb 26, 25 | -1.26 | - |
Nov 12, 24 | -0.92 | - |
Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
---|---|---|---|
Dec 31, 24 | 5.00 M Increased by +N/A% | -52.60 M Decreased by -113.95% | Decreased by -1.05 K% Decreased by N/A% |
Sep 30, 24 | 0.00 Decreased by -100.00% | -38.61 M Decreased by -208.42% | Decreased by N/A% Decreased by N/A% |
Jun 30, 24 | 0.00 Decreased by N/A% | -37.98 M Decreased by -30.74% | Decreased by N/A% Decreased by N/A% |
Mar 31, 24 | 0.00 - | -27.80 M - | Decreased by N/A% - |
Dec 31, 23 | 0.00 - | -24.59 M - | Decreased by N/A% - |
Sep 30, 23 | 50.00 M - | 35.61 M - | Increased by +71.22% - |
Jun 30, 23 | 0.00 - | -29.05 M - | Decreased by N/A% - |